Summary: Human UDP-glucuronosyltransferase (UGT) 1A1 is the enzyme that detoxifies neurotoxic bilirubin by conjugating it with glucuronic acid. UGT1A1 also plays a critical role in the detoxification and excretion of endogenous and exogenous lipophilic compounds mainly in the liver and gastrointestinal tract. Impaired or reduced UGT1A1 activity causes unconjugated hyperbilirubinemia (Gilbert's syndrome and Crigler-Najjar syndrome) and side effects of drug treatment such as SN-38 (active metabolite of the anticancer drug irinotecan)-induced toxicity. Understanding the regulatory mechanism of human UGT1A1 expression is critical in treating patients with unconjugated hyperbilirubinemia and for effective drug treatment. We identified the distal enhancer module of the UGT1A1 gene and a single nucleotide polymorphism in it that significantly reduces the transcriptional activity associated with the manifestation of Gilbert's syndrome. This review describes the transcriptional regulation of the human UGT1A1 gene by transcription factors and their co-factors, the genetic polymorphism associated with reduced transcriptional activity, and the induction of UGT1A1 expression by non-genetic factors including environmental factors and its pharmacological and toxicological meaning.
Introduction
UDP-glucuronosyltransferases (UGTs) play a critical role in the detoxification of endogenous and exogenous lipophilic substrates, in particular potentially toxic substrates, by conjugating them with glucuronic acid and thereby enhancing hydrophilicity for excretion in bile and urine. [1] [2] [3] In humans, UGTs are divided into two families, UGT1 and UGT2, based on amino acid sequence similarity.
4) The UGT2 family is subdivided into the UGT2A and UGT2B subfamilies, the genes for which are encoded by six unique exons located on chromosome 4 at q13. 5, 6) In contrast, the UGT1A family is encoded by a single gene at 2q37, with each UGT1A isoform consisting of a unique first exon following commonly used exons 2 to 5 through RNA splicing, and the first exons separated from each other by 5A-flanking regions 5-23 kb in length (Fig. 1A) . 3, [7] [8] [9] There are nine functional UGT1A enzymes (UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, and UGT1A10) and four pseudogenes (UGT1A2P, UGT1A11P, UGT1A12P, and UGT1A13P) in humans. 7) The quantitative determination of human UGT isoforms, using real-time PCR methods, indicates high expression in the liver, gastrointestinal tract (small intestine and colon), and kidney. 10) Hydrophobic bilirubin is a toxic product of heme that is detoxified mainly in the liver via conjugation with uridine diphosphate glucuronic acid.
1) The resulting hydrophilic bilirubin mono-and di-conjugate are then excreted in bile.
2) Among all of the UGT isoforms identified to date, UGT1A1 is the only relevant bilirubin-glucuronidating enzyme. The requirements for the glucuronidation of bilirubin for excretion were first elucidated based on the finding that the severe form of unconjugated hyperbilirubinemia in the absence of hemolysis or other liver disease, known as Crigler-Najjar type I syndrome, can be fatal. 11) Impaired or reduced UGT1A1 activity causes unconjugated hyperbilirubinemia (Crigler-Najjar syndrome and Gilbert's syndrome) 4) and decreases the glucuronidation of SN-38 (a pharmacologically active metabolite of the anticancer drug, irinotecan), leading to an increased risk for the development of severe irinotecan-associated toxicity. 12) Some genetic polymorphisms of drug-metabolizing enzymes in humans are associated with a reduction or enhancement in rates of drug metabolism. The levels of drug-metabolizing enzymes expressed in our body are also affected by non-genetic factors including environmental factors. This review describes the function of human UGT1A1 and the mechanism by which transcription factors induce UGT1A1 gene expression, the association of a defect in the UGT1A1 gene promoter with hyperbilirubinemia, and the modulation of UGT1A1 expression by environmental factors.
1. Function of UGT1A1
Bilirubin glucuronidation:
Bilirubin is considered to function as an antioxidant in a natural defense mechanism, particularly against exposure to oxygen at birth. [13] [14] [15] Bilirubin is removed from the body by the liver. Human bilirubin UDPglucuronosyltransferase activity in livers 1-10 days after birth is low at less than 10% of that in adults. 16) A functional deficit of CAR activity in neonatal human liver may account for low levels of bilirubin UDP-glucuronosyltransferase activity, which are associated with physiologic neonatal jaundice, together with an increased rate of erythrocyte turnover.
13) The IL-6-type cytokine oncostatin M, which is involved in the maturation of hepatocytes, has been shown to bind to its plasma membrane receptor and augment CAR-mediated signaling in vivo and in vitro through cross-talk via a mitogen-activated protein kinase cascade, resulting in enhanced UGT1A1 expression in mice and HepG2 cells. 17) Oncostatin M may contribute to the neonatal induction of UGT1A1 expression in liver via CAR. Neonatal humanized UGT1 mice (transgenic Ugt1-null mice carrying the human UGT1 locus) fed breast milk demonstrated reduced expression of intestinal UGT1A1 via inactivation of nuclear factor-¬B, leading to hyperbilirubinemia and bilirubin-induced neurological dysfunction. 14) For delayed expression of UGT1A1 in liver, intestinal UGT1A1 may contribute to the control of neonatal hyperbilirubinemia. A marked surge in hormones such as estradiol, progesterone, and glucocorticoids is found in late pregnancy. Our previous study 18) suggested that glucocorticoids could signal enhanced expression of UGT1A1 in response to increased demand in newborn infants to prevent or suppress icterus gravis neonatorum, via glucocorticoid receptor (GR) activation or GR enhancement of PXR-or decreasedneonatal CAR-mediated UGT1A1 regulation. Chen et al. 15) have shown that in neonatal humanized UGT1 mice but not neonatal Pxr-null or humanized UGT1 mice, hyperbilirubinemia is greatly reduced due to induction of hepatic UGT1A1 expression via PXR activation by dexamethasone; that is, PXR may be a key regulator of glucuronidation capacity modulating the severity of neonatal jaundice.
1.2 Endobiotic homeostasis and detoxification by UGT1A1: UGT1A1 has been shown to be involved in the conjugation of physiologically important endobiotic and xenobiotic compounds including clinical drugs such as acetaminophen, 19) entacapone (3-O-glucuronidation), 20) SN-38, etoposide, 21) and morphine (3-Oglucuronidation). 22) 17¢-Estradiol is a natural estrogen that is used in hormone replacement therapy. UGT1A1 together with UG-T1A3, UGT1A8, UGT1A10 (which possesses the highest conjugating activity), and UGT2B15 conjugate ent-17¢-estradiol to 3-O-glucuronide, in contrast to UGT2A1 and UGT2B7, which conjugate it at 17-OH.
23) The reduced UGT1A1 activity caused by xenobiotics could be associated with various adverse effects. Toxicologically, it is important to estimate whether drugs and exogenous compounds in environmental pollutants and diets affect UGT1A1 glucuronidation. Bilirubin and bilirubin glucuronides are unstable, but estradiol-3-glucuronidation has been shown to serve as an in vitro predictor for interaction with bilirubin glucuronidation. 24) Estrogen has been demonstrated to act as an endometrial carcinogen and 2-methoxyestradiol, a product of the conjugation of its metabolite 2-hydroxyestradiol by cathechol-O-methyltransferase, has been shown to disrupt microtubule function and protect against tumors in animals. 25) UGT1A1 exhibits a preference for the glucuronidation of 2-hydroxyestradiol 26) and lower expression of UGT1A1 in subjects with the UGT1A1*28 allele (A[TA] 7 TAA) could decrease the risk of endometrial cancer by reducing the excretion of 2-hydroxyestradiol. 27) Moreover, patients with reduced enzymatic activity due to a genetic polymorphism of UGT1A1 have a higher risk of developing severe hematological toxicity and/or diarrhea when taking the anticancer drug irinotecan. Sai et al. 28) have conducted a comprehensive haplotype analysis of the UGT1A1 gene, including the enhancer, the promoter, and all 5 exons and their flanking regions, from 195 Japanese subjects and investigated the association of these haplotypes with area under the concentrationtime curve (AUC) ratios (7-ethyl-10-hydroxycamptothecin glucuronide [SN-38G]/irinotecan metabolite 7-ethyl-10-hydroxycamptothecin and pretreatment levels of serum total bilirubin in 85 cancer patients who received irinotecan). They have demonstrated highly significant associations between the haplotypes of UGT1A1*28 (A[TA] 7 TAA) and both a reduced AUC ratio and an increased total bilirubin level and between the haplotypes of UGT1A1*60 (T¹3279G) and an increased total bilirubin level, and that the reduction in the AUC was remarkable in combination with *6 (G211A)/*60 (T¹3279G) or *6 (G211A)/*28 (A[TA] 7 TAA).
Identification of a Defect in the UGT1A1 Gene Promoter and Its Association with Hyperbilirubinemia
A reduction of UGT1A1 activity causes unconjugated hyperbilirubinemia (Crigler-Najjar syndrome and Gilbert's syndrome). Many UGT1A1 mutant alleles responsible for clinical hyperbilirubinemia have been identified. 4, 29) Genetic lesions causing an absence of UGT1A1 activity result in Crigler-Najjar syndrome type I, which is characterized by potentially lethal hyperbilirubinemia (serum total bilirubin level, 20 [30] [31] [32] and a missense mutation involving a G to A substitution at nucleotide 211 in exon 1 of UGT1A1 (G211A; also known as G71R) (UGT1A1*6), [33] [34] [35] both result in decreased bilirubin-glucuronidating activity and lead to mildly elevated serum bilirubin levels. 30, 36, 37) 39) The mild hyperbilirubinemia seen in individuals with Gilbert's syndrome has been reported to be linked to homozygous A[TA] 7 TAA and G211A mutations. 5, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] Although G211A is the most common mutation encountered in Japanese patients with Gilbert's syndrome, the majority of these mutations are heterozygous and the transferase activity level (60% of normal) is somewhat too high to explain the development of mild hyperbilirubinemia. 37) Because the hepatic UGT1A1 activity in patients with Gilbert's syndrome is decreased to about 30% of normal, 42, 43) additional factors have been thought to contribute to the development of this syndrome. We identified a new type of polymorphism in the phenobarbital-responsive enhancer module (gtPBREM) of the UGT1A1 gene. This consisted of a single nucleotide polymorphism in which the T normally present at nucleotide ¹3279 was replaced by G (UGT1A1*60).
44) The frequency of alleles carrying the T¹3279G mutation was significantly higher in the adult hyperbilirubinemic group (0.55) than in the adult control group (0.22; p < 0.001). The frequencies of alleles for the A[TA] 7 TAA and exon 1 mutations were also significantly higher in the hyperbilirubinemic group (0.29 and 0.34, respectively) than in the control group (0.01 and 0.16, respectively). In Japanese control and hyperbilirubinemic groups, we found subjects with the T¹3279G mutation alone, indicating that the T¹3279G and A[TA] 7 TAA mutations are not linked. The plasma total bilirubin levels of the subjects with G211A were significantly higher than those of the subjects with no mutations (p < 0.01). Moreover, levels in the double heterozygotes for T¹3279G and G211A were significantly higher than those in the normal subjects (p < 0.001), the heterozygotes for T¹3279G (p < 0.01), and the subjects with G211A (p < 0.05). These observations indicate that double heterozygous mutations in the UGT1A1 gene promoter (T¹3279G) and exon 1 (G211A) may result in more strongly reduced transferase activity than a single heterozygous mutation.
To date, more than 113 mutations causing familial non-hemolytic unconjugated hyperbilirubinemia (Crigler-Najjar syndrome and Gilbert's syndrome) have been identified. 29) Almost all mutations first demonstrated were UGT1A1 gene polymorphisms associated with Crigler-Najjar syndrome and predicted the substitution of a single amino acid resulting in the reduction of UGT1A1 activity. In addition to the structural mutations, a recent study demonstrates that patients with Crigler-Najjar syndrome type II are compound heterozygotes for A[TA] 7 TAA and the G923A mutation in exon 2 of UGT1A1 (known as G308E) (UGT1A1*11). 45) Thus, mutations of both the enhancer/promoter region and the coding region including the intron-exon junctions should be determined in patients with Crigler-Najjar syndrome and Gilbert's syndrome. Crigler-Najjar syndrome is an autosomal recessive condition caused by a complete (type I) or incomplete (type II) deficiency of hepatic bilirubin UGT1A1 activity. Phenobarbital has been used for reducing the serum bilirubin load in Crigler-Najjar type II patients. [46] [47] [48] [49] [50] Since the constitutive androstane receptor (CAR; NR1I3) has been identified as the transcription factor regulating the phenobarbital-responsive enhancer module (PBREM) in response to phenobarbital, 51) we wondered whether CAR regulates phenobarbital-inducible transcription of the human UGT1A1 gene. As the mouse CAR ligand TCPOBOP increased UGT1A1 mRNA levels in mouse CAR-overexpressing HepG2 cells, the UGT1A1 gene appeared to be directly regulated by CAR. 52) To elucidate the location of the CAR-regulated enhancer element in human UGT1A1, various DNA fragments were generated from an 11-kbp 5A-flanking region of the gene, and their enhancer activities were examined in HepG2 cells co-transfected with a human CAR-expression plasmid. Thus, we identified the UGT1A1 gtPBREM at ¹3499/ ¹3210 from the transcription start site, which is regulated by the nuclear receptor known as CAR in response to phenobarbital treatment ( Table 1 and Fig. 1) . 52) Nucleotide sequence analysis of the 290-bp DNA revealed 3 potential nuclear receptor motifs, each separated by about 90 bases, similar to PBREM containing 2 nuclear receptor motifs (Fig. 2) . From the 5A-end, these motifs were named DR4, gtNR1, and DR3, respectively. The sequence of gtNR1 is highly homologous to the NR1 site within the 51-bp PBREM conserved in the human CYP2B6 gene (Fig. 2) . Mutation of gtNR1 resulted in a 100% decrease in the CAR-dependent enhancer activity. On the other hand, a single mutation of either DR4 or DR3 reduced the original activity by about 50%. These results indicate that gtNR1 plays the most significant role in the activation of the 290-bp DNA by CAR. However, DR4 and DR3 appeared to be required to confer full enhancer activity to the 290-bp reporter gene.
Induction of human UGT1A1 expression mediated through a distal enhancer module by xenobiotics
To test whether sequences upstream of the 5A-flanking region of UGT1A1 contribute to the activation by xenobiotics, we tested various DNA fragments generated from a 11-kbp 5A-flanking region in UGT1A1 and placed in front of the reporter luciferase gene for enhancer activities induced by methoxychlor (CAR activator), rifampicin [pregnane X receptor (PXR; NR1I2) activator], and benzo[a]pyrene [aryl hydrocarbon receptor (AhR) activator]. We identified and characterized a distal enhancer module at ¹3499/¹3210 that directs the transactivation of the UGT1A1 gene induced by methoxychlor, rifampicin and benzo[a]pyrene. 53) Strikingly, this element is the same as gtPBREM.
The 290-bp distal enhancer module is a complex array of transcription factor-binding sites. To define the roles of each nuclear receptor (NR) motif in the CAR-or PXR-dependent activation of the 290-bp reporter gene, five motifs were singularly mutated. Mutation of gtNR1 (¹3382/¹3367) resulted in a 100% decrease in both rifampicin-induced PXR-dependent enhancer activity and CAR-dependent enhancer activity. [52] [53] [54] The electrophoretic mobility shift assay also indicated that the mixture of CAR with the retinoid X receptor (RXR) or PXR with RXR bound to gtNR1 specifically. Thus, gtNR1 was the major binding site of the CAR: RXR or PXR: RXR heterodimer. These results indicate that gtNR1 plays the most significant role in the activation of the 290-bp DNA by CAR and PXR ( Table 1) . 3.1.3 Mechanism of activation of CAR and PXR in human UGT1A1 gene expression CAR and PXR are orphan nuclear hormone receptors, which lack known physiological ligands, activated by a wide range of structurally unrelated drugs/xenobiotics. [55] [56] [57] [58] [59] [60] Both receptors are recognized as xenobiotic-sensing nuclear receptors that transcriptionally regulate the expression of phase I, II, and III metabolic enzymes and transporters involved in the metabolism and elimination of endogenous and exogenous substances such as bilirubin, steroid hormones, and xenobiotics. PXR is structurally characterized by functionally distinct domains: an N-terminal transcriptional activation domain (AF-1), a DNA-binding domain, a hinge region, and a C-terminal ligand-binding domain, whereas CAR contains the DNA-binding domain, hinge region, and ligandbinding domain but no AF-1 domain. 61, 62) Glucocorticoid receptorinteracting protein 1 (GRIP-1) interacts with the C-terminus (AF-2 domain in the ligand-binding domain) of human CAR and PXR, 18) and GRIP-1 mediates the ligand-independent nuclear translocation and activation of CAR in mouse liver. 63) Mouse and human CAR and PXR form a complex with the co-chaperone partners cytoplasmic CAR retention protein (CCRP; designated Dnajc7 in the NCBI data base) and heat shock protein (HSP) 90 to maintain their cytoplasmic localization. [64] [65] [66] 3.1.3.1 CAR activation signaling: Phenobarbital does not directly bind to rodent and human CAR, but causes nuclear accumulation of rodent and human CAR in primary hepatocytes and intact livers, although nuclear translocation of human CAR is spontaneous in immortalized cell lines. 57, 67) Extracellular signalregulated kinase is considered to be an endogenous signal retaining CAR in the cytoplasm of mouse primary hepatocytes. 68, 69) Upon exposure to phenobarbital, protein phosphatase 2A recruits the CAR complex, and CAR is dissociated from the complex with CCRP and HSP90 on microtubules of mouse liver cells. 65, 70) This event triggers CAR's translocation from the cytoplasm to nucleus, where it interacts with RXR to form a heterodimer and coactivators such as steroid receptor co-activator 1 (SRC-1) 71) and activates transcription by binding to nuclear receptor DR4 sites in the phenobarbital-responsive element (PBREM) of the target gene. In addition, since CAR translocates into the nucleus when mouse and human CAR and protein phosphatase 1, regulatory subunit 16A (PPP1R16A), are coexpressed in mouse liver, PPP1R16A is considered to signal nuclear translocation of CAR. 72) The translocation of CAR into the nucleus is an important step in the activation of CAR, which is regulated by cell signals including phosphorylation/dephosphorylation. Threonine 38 of human CAR was identified as the target of dephosphorylation by protein phosphatase 2A.
73) The signaling pathway for human CAR activation is proposed in Figure 3A . Kanno et al. 74) have revealed that the nuclear import of rat CAR is regulated by the importin-Ran system, which is required for maintaining an intact microtubule network. In contrast, 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl) oxime (CITCO) directly binds to the ligand-binding domain of human CAR, and exhibited preferred induction of CYP2B6 over CYP3A4 in hepatocytes. 55, 75) The AMP-activated protein kinase (AMPK) activator 5-amino-imidazole carboxamide riboside induced CYP2B6 gene expression in human hepatocytes. 76) AMPK has been demonstrated to mediate phenobarbital's induction of CYP2B6 expression in a ligand-independent manner, but not CITCO's induction in a ligand-dependent manner. 77, 78) Furthermore, Shizu et al. 79) demonstrated that phenobarbital down-regulated microRNA-122, a liver-enriched microRNA involved in both hepatic differentiation and function, and suppressed the transactivity of the microRNA-122 promoter, and that an inhibitory RNA specific for microRNA-122 increased activated AMPK and CAR-mediated transactivation of the phenobarbital-responsive enhancer module in mouse liver and HepG2 cells. MicroRNA-122 may help to suppress the CAR-UGT1A1 pathway. specific amino acid residues has been demonstrated to modulate the cytoplasmic localization and the nuclear activation which affect the PXR activity. [80] [81] [82] We investigated the mechanism by which human PXR's activation induces UGT1A1 expression in a ligandindependent manner using the cyclin-dependent kinase (CDK) inhibitor roscovitine and in a PXR ligand rifampicin-inducible manner, and propose the signaling pathway for PXR compared with that for CAR (Fig. 3A) . 83) Some of the residues involved in PXR's activation by roscovitine and rifampicin are different. The phosphomimetic mutation at S305 more strongly reduced the ligand (rifampicin)-inducible transcriptional activity compared with the ligand-independent activation by roscovitine, indicating that the residue at S305 in the ligand-binding domain plays an important role in the ligand-dependent PXR activation. On the other hand, a phosphomimetic mutation at T290 suppressed the translocalization of the YFP-PXR fusion protein from the cytoplasm to nucleus, and reduced the transcriptional activity of PXR in cells stimulated by roscovitine and rifampicin. Phosphorylation at T290 is likely to suppress the roscovitine-and rifampicin-induced dissociation of PXR from HSP90 and CCRP, resulting in the accumulation of the PXR protein in the cytoplasm. The protein phosphatase PP1/PP2A inhibitor okadaic acid has been shown to abolish PXR activity, but the mechanism of PXR's activation by dephosphorylation is not clear. 83) Further study is needed to clarify the mechanism of transactivation of PXR and CAR from the cytoplasm to nucleus through specific cross-talk with various signaling pathways.
PXR activation signaling: Phosphorylation of PXR at
3.1.3.3 Regulation by protein kinases/phosphatases: Protein kinase A (PKA) and protein kinase C (PKC) contribute to cell signaling involved in ligand-inducible PXR activation. 84, 85) PKCdependent signaling has been demonstrated to repress the transcriptional activity of PXR by increasing the strength of interaction between PXR and the nuclear receptor co-repressor protein. 84) Lichti-Kaiser et al. 85) demonstrated that PKA signaling has a repressive effect upon PXR-mediated gene activation in human hepatocytes and stimulates the interaction of PXR with the nuclear receptor co-repressor. We demonstrated that hepatocyte growth factor increased UGT1A1 expression as did the endogenous CDK inhibitors p16, p21, and p27 in HepG2 cells, and concluded that the expression of UGT1A1 is negatively regulated through a CDK2 signaling pathway linked to cell cycle progression in HepG2 cells.
86) The deletion of CDK2 using siRNA resulting in enhanced UGT1A1 expression and the wild-type PXR protein but not S350D mutant was phosphorylated by CDK2, indicating that CDK2 phosphorylates the S350 residue of the PXR protein, resulting in impaired PXR activity. 83, 87) Thus, CAR and PXR activities are regulated in a cell cycle-dependent manner, influencing the expression of drug-metabolizing enzymes such as UGT1A1, CYP2B6, and CYP3A4. 86, 88) 3.2 Transcriptional regulation of UGT1A1 gene expression by AhR and nuclear factor (erythroid-derived-2)-like-2 (Nrf2): 3.2.1 Transcriptional regulation of UGT1A1 gene expression by AhR AhR, CAR, and PXR are major xenobiotic receptors, which are expressed predominantly in the liver and intestine, and regulate the transcriptional activation of genes encoding phase I, II, and III drug metabolizing enzymes and transporters and subsequently have been found to potentiate a variety of biological effects associated with pharmacological and toxicological consequences. Unlike CAR and PXR, AhR is a basic helix-loop-helix (bHLH) protein of the Per-Arnt-Sim (PAS) family of transcription factors liganded by environmental halogenated aromatic hydrocarbons and polyaromatic hydrocarbons as well as clinically used drugs. [89] [90] [91] AhR is structurally characterized by two domains: the bHLH domain, which functions as a dimerization interface, and the PAS domain in the N-terminal half of the molecule. Unliganded AhR exists in the cytoplasm in a complex consisting of a dimer of the molecular chaperone HSP90, the co-chaperone protein p23, and an immunophilin-related protein hepatitis B virus X-associated protein 2 (XAP2) (Fig. 3B) . 92, 93) The xenobiotic response element (XRE) involved in AhR-mediated induction was identified at ¹3334/¹3315 using a combination of deletion or mutation assays of the UGT1A1 gene and electrophoretic mobility shift assays with AhR and aryl hydrocarbon nuclear translocator (ARNT) antibodies ( Table 1) . 94) Similar to CAR and PXR activation, following activation by exogenous as well as endogenous ligands, 95, 96) AhR translocates to the nucleus where it binds to its heterodimeric partner ARNT, then HSP90 dissociates from AhR and binds to a XRE located in the promoter of its target genes. 97) Mutation of the XRE significantly reduced the enhancing effects of flavones such as chrysin and baicalein, indicating that UGT1A1 is inducible in response to flavones through the transactivation of gtPBREM. 53) 
Transcriptional regulation of UGT1A1 gene expression by Nrf2
Yueh and Tukey 98) investigated UGT1A1 regulation in response to oxidative stress, and found that when HepG2 cells were treated with the prooxidants tert-butylhydroquine and ¢-naphthoflavone, which have been shown to activate the transcription factor Nrf2, cellular UGT1A1 activities were increased. Nrf2 is a basic leucin zipper transcription factor which belongs to the Cap-N-Collar family and regulates the transcription of cytoprotective and antioxidant genes through binding to the antioxidant-response element (ARE) in their promoters. As the cellular and molecular mechanism of Nrf2 activation, it has been demonstrated that Nrf2 is captured in the cytoplasm by Kelch-like-ECH-associated protein 1 (Keap1) (Fig. 3B) . 99) On oxidative modification of Keap1 or phosphorylation of Nrf2, it is released from Keap1 cytoplasmic capture and moves to the nucleus where it binds to its heterdimeric partner Maf proteins to regulate the activation of ARE-dependent gene expression. 100) A direct role for Nrf2 in the induction of UGT1A1 expression has been shown in Nrf2 knockdown experiments with small interfering RNA that ablated the effect of tertbutylhydroquinone on UGT1A1.
98) The ARE involved in the Nrf2-mediated induction was identified at ¹3344/¹3336 and ¹3335/ ¹3327 using a combination of deletion or mutation assays of the UGT1A1 gene and electrophoretic mobility shift assays of Nrf2 binding to the UGT1A1-ARE with nuclear extracts from tertbutylhydroquinone-treated HepG2 cells ( Table 1) . 98) Nrf2-Keap1-dependent UGT1A1 induction by prooxidants has been considered to represent a key adaptive response to cellular oxidative stress that defends against a variety of environmental insults. 98, 101) 
Activation of XRE and ARE
The regulation of XRE and ARE is generally thought to have distinct pathways, but Nrf2 is directly modulated by the AhR-XRE activation 102) and Nrf2 regulates the expression of AhR and vice versa.
103) The AhR inducer TCDD has been demonstrated to induce human NADP(H):quino-oxidoreductase (NQO1) gene expression through ARE activation, 104) indicating cross-talk between the XRE and ARE pathways. Since the human UGT1A1 gene enhancer module bound to Nrf2 (ARE2) contains a binding site for AhR, there may be cross-talk between Nrf2 and AhR in the UGT1A1 induction. For interaction between Nrf2 and AhR in the regulation of human UGT1A10, Kalthoff et al. 105) have suggested that cellular protection by glucuronidation is inducible by xenobiotics via AhR and by oxidative metabolites via Nrf2 linking glucuronidation to cellular protection and defense against oxidative stress.
3.3 Transcriptional regulation of human UGT1A1 gene expression by GR: The induction of UGT1A1 expression by the synthetic glucocorticoid dexamethasone has been extensively documented both in vivo in the liver and in vitro in cultured rat hepatocytes. 106, 107) In addition, treatment with dexamethasone at 10 ¹7 mol/l caused a slight but significant increase in UGT1A1 mRNA and protein in HepG2 cells. 18) Moreover, 10 ¹7 mol/l dexamethasone enhanced 5 © 10 ¹6 mol/l rifampicin-and 5 © 10
¹6
mol/l clotrimazole (CAR activator)-inducible expression of UGT1A1 mRNA and protein in HepG2 cells. In HepG2 cells with exogenously expressed CAR and PXR, a submicromolar concentration of dexamethasone slightly but significantly enhanced the reporter activity of the 290-bp distal enhancer module. GR (NR3C1) in the absence of hormones exists in the cytoplasm in a complex consisting of a dimer of HSP90, HSP70, the co-chaperone protein p23, and immunophilins. The molecular mechanism of GR activation is believed to involve binding of a ligand to the receptor, altering its protein conformation to expose the activation function-2, allowing interaction with coactivators such as SRC-1 and glucocorticoid receptor-interacting protein 1 (GRIP1), and activating transcription. The activated GR translocates to the nucleus and binds to a glucocorticoid-response element (GRE) located in the promoter of its target genes (Fig. 3A) . 108, 109) We investigated the molecular mechanism of human UGT1A1 induction by glucocorticoids at submicromolar concentrations and the functional cross-talk between GR and CAR/PXR. Using site-directed mutagenesis and electrophoretic mobility shift assays, we identified the GR-mediated GRE at ¹3404/¹3389 and ¹3251/¹3236 close to the CAR/PXR response element gtNR1(¹3382/¹3367) ( Table 1) .
18)
Activated GR enhanced CAR/PXR-mediated UGT1A1 regulation with the transcriptional cofactor GRIP1, indicating that GR may be involved synergistically in the xenobiotic-responsive regulation of UGT1A1 by CAR/PXR.
3.4 Transcriptional regulation of UGT1A1 gene expression by peroxisome proliferator-activated receptor ¡ (PPAR¡): Three major isoforms of PPARs, PPAR¡ (NR1C1), PPAR¢ (NR1C2), and PPAR£ (NR1C3), are members of the superfamily of nuclear transcription factors, the activation of which depends on the binding of the ligand. PPARs reveal a predominantly nuclear distribution in the presence and absence of a PPAR ligand, and colocalize with the heterodimeric partner RXR at specific locations within the nucleus (Fig. 3B) . 110) PPAR¡ is considered to contribute to the transcriptional regulation of genes encoding proteins associated with lipid metabolism and transport. We examined the effect of a high-fat and high-sucrose diet on the expression of transcription factors associated with lipid metabolism in liver cell nuclei of rats, and found that CAR and PPAR¡ protein levels were increased, correlated with enhanced expression of UGT1A1 and UGT1A6. 111) Administration of the PPAR¡ agonist clofibrate to rats upregulated the UGT1A1 and UGT1A6 expression.
111) Additionally, in human hepatocytes and humanized UGT1A mice treated with the PPAR¡ agonist 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643), UGT1A1, UGT1A3, UGT1A4, and UGT1A6 have been identified as targets of PPAR¡. [112] [113] [114] A PPAR¡ responsive element (PPRE) was identified at ¹3294/¹3282 using a combination of deletion or mutation assays of the UGT1A1 gene and electrophoretic mobility shift assays. 112 ) Surprisingly, all these elements (gtNR1, XRE, ARE, GRE, and PPRE) are located within the 290-bp distal enhancer module of the human UGT1A1 gene ( Fig. 1 and Table 1 ).
3.5 Roles of hepatocyte nuclear factor (HNF) 1¡ and HNF4¡ in UGT1A1 gene expression: We demonstrated that HNF1¡ is required for transactivation of the human UGT1A1 gene by CAR, PXR, AhR, and GR.
115) The 181-bp region upstream of the transcription start site involves the hepatocyte nuclear factor (HNF) 1¡-binding site (¹95/¹79) (Fig. 1B) .
116) The HNF1¡-binding site was mutated to assess whether HNF1¡ contributes to the basal transcriptional activity of the distal enhancer module (¹3570/ ¹3180) linked to the proximal 181-bp region upstream of the transcription start site. 115) HNF1¡ bound to the proximal promoter motif not only enhances the basal reporter activity of the UGT1A1 distal enhancer module linked to the proximal UGT1A1 promoter, but also influences the transcriptional regulation of UGT1A1 by CAR, PXR, GR, and AhR to markedly enhance reporter activities. Mutation of the HNF1¡-binding site in the UGT1A1 proximal promoter abolishes the basal promoter function. The CAR-, PXR-, GR-, and AhR-mediated transcriptional activities of the UGT1A1 distal enhancer module linked to the HNF1¡-binding site-mutated promoter were reduced to levels similar to the CAR-, PXR-, GR-, and AhR-mediated transcriptional activities of gtPBREM. Thus, HNF1¡ appears to maximize the transcriptional activities of the other transcription factors such as CAR, PXR, GR, and AhR. 115) In addition, basal human UGT1A1 expression in colon cancer cells has been shown to be positively regulated by HNF1¡ and an upstream stimulating factor, and negatively regulated by DNA methylation in the binding site of the upstream stimulating factor. 116) Downregulation of the liver-enriched transcription factor HNF4¡ (NR2A1) by small interfering RNA in human hepatocytes was demonstrated to decrease the mRNA levels of drug-metabolizing enzymes including UGT1A1 as well as PXR and CAR, 117) but there was no correlation between HNF4¡ and UGT1A1 mRNA levels in human livers. 118 ) Since HNF4¡'s interaction with the coactivator peroxisome proliferator-activated receptor £ coactivator-1¡ (PGC-1¡) directly regulates CAR gene expression through the HNF4¡-response element located in the proximal promoter of CAR, 119) UGT1A1 gene expression appears to be influenced indirectly through CAR's induction by HNF4¡.
Human UGT1A1 is mainly expressed in the liver and gastrointestinal tract including the stomach, small intestine, and colon; the mRNA levels are greatest in the liver (1.00), then small intestine (0.41), colon (0.26), and stomach (0.07). 10) As described above, the expression of UGT1A1 is regulated by tissue-specific and ligand-activated transcription factors. Collectively, the expression of UGT1A1 in the liver is induced by activators of all five pathways via CAR, PXR, AhR, PPAR¡, and Nrf2, which contribute to drug/xenobiotic metabolism as central regulators.
Future Directions
Mutations found in patients with Crigler-Najjar syndrome type II and Gilbert's syndrome do not completely abolish the enzymatic activity. Phenobarbital can be an effective drug for both of these diseases and for increasing the expression of a partially active UGT1A1 enzyme. However, phenobarbital has the serious disadvantage of inducing sleep. Bilirubin levels have been demonstrated to be influenced by not only genetic factors but also nongenetic factors such as hemoglobin levels, body mass index, and fasting time. 120) We have demonstrated that the expression of UGT1A1 is increased by dietary flavones (luteolin, apigenin, chrysin, and baicalein) and synthetic flavones (flavone, 3-, 5-, and 7-hydroxyflavones, and ¡-naphthoflavone) but not by black tea polyphenols or green tea polyphenols in HepG2 cells. 53) Kundu et al. 101) have revealed that carinoside, a flavone glycoside from Cajanue cajan leaf, reduced hepatic bilirubin accumulation in the liver of rats administered CCl 4 by stimulating bilirubin UGT1A1 activity through Nrf2 gene expression. Carinoside appears to show greater bioavailability than chrysin, to escape from intestinal glucuronidation. Additionally, garlic extract diallyl sulfide has been shown to activate CAR to induce CAR-mediated gene expression. 121) Thus, the modulation of UGT1A1 expression by dietary factors is of considerable interest. The screening of dietary compounds affecting the expression of drug-metabolizing enzymes/drug transporters will lead to protection against side effects, achieving more advanced therapeutic effects with smaller dosages of drugs, and reducing medical costs. Studies on the combined effects of drugs and food on drug metabolism in human subjects with different genetic backgrounds are expected for tailor-made medical treatment.
